UNH will announce Q1 results and conduct a conference call tomorrow at 8:45 a.m. ET.
The estimated Q1 EPS is $6.08, with sales growth of 12% to $89.77 billion. FY23 guidance includes an EPS of $24.40-$24.90 and revenues of $357-$360 billion.
The LHC Group merger was finalized in February, the UK CMA's EMIS Group Plc probe moved to phase 2, and the DoJ stopped trying to block the Change Healthcare merger. Raymond James upgraded UNH and Cigna, and Morgan Stanley named UNH as their top pick. UNH trades at a small premium compared to Humana and Cigna.
TLDR
Q1 EPS estimated at $6.08, sales growth of 12% to $89.77 billion
FY23 guidance: $24.40-$24.90 EPS, $357-$360 billion revenues
LHC Group merger closed, UK CMA probe advances, DoJ drops Change Healthcare merger block
TECHS:
UNH upgraded by Raymond James, named Top Pick by Morgan Stanley
UNH trades at about 20.9x forward earnings estimates, a modest premium to peers like Humana (HUM at 18.9x) and Cigna (CI at 10.5x).
If you liked this content please click the ❤️ below and/or share this post.
SHAMLESS PLUGS
CLICK HERE TO CHECK OUT MY 2022 PREVIEW OPINION PACKET. OVER 80 PAGES OF CONTENT AND INFORMATION AVAILABLE HERE.
TOTALLY FREE Trading Packet!
Click here to get my packet that shows you how I traded $600 into $100K FOR FREE.
This packet will explain to you in depth how I trade and how I manage my risk.
I am happy to share this. Just use the code KPAKFRAUD at checkout and you will get it TOTALLY FREE. You will pay absolutely nothing.
Check out the latest episodes on my YouTube above.